gvtcx

NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals

NHS England Published 6 Apr 2023 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£719,558,000
Statuscomplete
Category (CPV) 33600000
Deadline12 Dec 2022
Procedureopen
OCIDocds-h6vhtk-0380b4

Awards (50)

This procurement was awarded to 50 suppliers. Values shown are per-award; the notice total is £719,558,000.

SupplierValueDateStatus
Accord-UK Ltd shared · · active
Aspen Pharmacare UK Limited shared · · active
Aspire Pharma Limited shared · · active
Astellas Pharma Ltd shared · · active
Aventis Pharma ltd t/a Sanofi shared · · active
Bayer Plc shared · · active
Chiesi Limited shared · · active
CST Pharma Limited shared · · active
Day Lewis Medical Ltd shared · · active
Dexcel Pharma Ltd shared · · active
Drugsrus Ltd shared · · active
Eli Lilly and Company Ltd shared · · active
Ferring Pharmaceuticals Ltd shared · · active
Gedeon Richter UK Ltd shared · · active
Gerot Lannach UK Ltd shared · · active
Glenmark Pharmaceuticals Europe Limited shared · · active
Ipsen shared · · active
Janssen-Cilag Ltd shared · · active
Kent Pharma Ltd shared · · active
Lupin Healthcare (UK) Limited shared · · active
Martindale Pharma shared · · active
medac Pharma LLP shared · · active
Merck Serono Limited shared · · active
Mercury Pharmaceuticals Limited shared · · active
Morningside Pharmaeuticals shared · · active
Mylan shared · · active
Napp Pharmaceuticals Ltd shared · · active
Neuraxpharm UK Ltd shared · · active
Nordic Pharma shared · · active
Norgine Pharmaceuticals Limited shared · · active
Novartis Pharmaceuticals UK Ltd shared · · active
Orifarm UK shared · · active
Otsuka Pharmaceuticals UK Limited shared · · active
Pfizer Ltd shared · · active
Pharmasure shared · · active
QDEM PHARMACEUTICALS LIMITED shared · · active
Recordati Rare Diseases UK Ltd shared · · active
Ridge Pharma shared · · active
ROVI Biotech Ltd shared · · active
Sandoz Ltd shared · · active
Selective Supplies Ltd. shared · · active
Synchrony shared · · active
Takeda UK Ltd shared · · active
Tetris Pharma Lts shared · · active
Teva UK Limited shared · · active
Theramex HQ UK shared · · active
Tillomed Laboratories ltd shared · · active
Wockhardt UK Limited shared · · active
Xiromed shared · · active
Zentiva Pharma UK Ltd shared · · active

description

NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals<br/><br/>Offer reference number: CM/PHR/22/5675<br/><br/>CM/PHR/22/5675/01 - NHS Framework Agreement for Branded Medicines – National Category Tender Lot 1. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/><br/>CM/PHR/22/5675/02 - NHS Framework Agreement for Branded Medicines – National Tender Lot 2. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
10 Nov 2022 Contract notice (F02) Earlier regulations 031803-2022
6 Apr 2023 Contract award notice (F03) Earlier regulations 010254-2023

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.